Merck (MRK GY) FY 2025 (EUR): EPS 8.34 (exp. 8.34), Net revenue 21.1bln (prev. 21.2bln Y/Y), guides 2026 revenue between 20.0-21.18 (exp. 21.2bln), proposes dividend of EUR 2.20/shr

Merck's FY 2025 results met EPS expectations but showed a slight revenue decline year-on-year, indicating a potential softening in their business momentum. The guidance for 2026 falls short of consensus, suggesting cautiousness in their outlook, although the proposed dividend reflects a commitment to returning value to shareholders. Overall, traders should monitor how this affects near-term sentiment in the pharmaceuticals sector and broader equities market.